nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—Blood pressure systolic increased—Sorafenib—thyroid cancer	0.0685	0.126	CcSEcCtD
Amphetamine—TAAR1—neck—thyroid cancer	0.0522	0.206	CbGeAlD
Amphetamine—Sudden death—Vandetanib—thyroid cancer	0.0288	0.0528	CcSEcCtD
Amphetamine—CARTPT—thyroid gland—thyroid cancer	0.0249	0.098	CbGeAlD
Amphetamine—TAAR1—thyroid gland—thyroid cancer	0.0249	0.098	CbGeAlD
Amphetamine—CARTPT—head—thyroid cancer	0.0221	0.0869	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—NKX2-1—thyroid cancer	0.0194	0.0967	CbGpPWpGaD
Amphetamine—CARTPT—lymph node—thyroid cancer	0.0154	0.0609	CbGeAlD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—RET—thyroid cancer	0.0117	0.0584	CbGpPWpGaD
Amphetamine—TAAR1—G alpha (s) signalling events—CALCB—thyroid cancer	0.0105	0.0523	CbGpPWpGaD
Amphetamine—Blood pressure increased—Sorafenib—thyroid cancer	0.00994	0.0182	CcSEcCtD
Amphetamine—SLC22A3—saliva-secreting gland—thyroid cancer	0.00986	0.0388	CbGeAlD
Amphetamine—MAOB—saliva-secreting gland—thyroid cancer	0.00912	0.0359	CbGeAlD
Amphetamine—SLC18A2—thyroid gland—thyroid cancer	0.00845	0.0333	CbGeAlD
Amphetamine—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00844	0.0155	CcSEcCtD
Amphetamine—Weight decreased—Vandetanib—thyroid cancer	0.00837	0.0153	CcSEcCtD
Amphetamine—Depression—Vandetanib—thyroid cancer	0.00822	0.0151	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00817	0.015	CcSEcCtD
Amphetamine—Urinary tract infection—Vandetanib—thyroid cancer	0.00801	0.0147	CcSEcCtD
Amphetamine—SLC18A2—head—thyroid cancer	0.00749	0.0295	CbGeAlD
Amphetamine—Cardiomyopathy—Epirubicin—thyroid cancer	0.00718	0.0132	CcSEcCtD
Amphetamine—SLC22A5—saliva-secreting gland—thyroid cancer	0.00717	0.0282	CbGeAlD
Amphetamine—Erythema multiforme—Vandetanib—thyroid cancer	0.007	0.0128	CcSEcCtD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—RET—thyroid cancer	0.00697	0.0348	CbGpPWpGaD
Amphetamine—Mood swings—Sorafenib—thyroid cancer	0.00684	0.0125	CcSEcCtD
Amphetamine—Cardiomyopathy—Doxorubicin—thyroid cancer	0.00664	0.0122	CcSEcCtD
Amphetamine—Abdominal pain upper—Sorafenib—thyroid cancer	0.00659	0.0121	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.0065	0.0119	CcSEcCtD
Amphetamine—Tremor—Vandetanib—thyroid cancer	0.00604	0.0111	CcSEcCtD
Amphetamine—SLC22A3—thyroid gland—thyroid cancer	0.00602	0.0237	CbGeAlD
Amphetamine—Erectile dysfunction—Sorafenib—thyroid cancer	0.00575	0.0105	CcSEcCtD
Amphetamine—SLC6A3—head—thyroid cancer	0.00567	0.0223	CbGeAlD
Amphetamine—Weight decreased—Sorafenib—thyroid cancer	0.00564	0.0103	CcSEcCtD
Amphetamine—Convulsion—Vandetanib—thyroid cancer	0.00558	0.0102	CcSEcCtD
Amphetamine—MAOB—thyroid gland—thyroid cancer	0.00557	0.0219	CbGeAlD
Amphetamine—Hypertension—Vandetanib—thyroid cancer	0.00556	0.0102	CcSEcCtD
Amphetamine—SLC22A5—trachea—thyroid cancer	0.00553	0.0218	CbGeAlD
Amphetamine—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00551	0.0101	CcSEcCtD
Amphetamine—Chest pain—Vandetanib—thyroid cancer	0.00549	0.01	CcSEcCtD
Amphetamine—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00548	0.01	CcSEcCtD
Amphetamine—Anxiety—Vandetanib—thyroid cancer	0.00547	0.01	CcSEcCtD
Amphetamine—Myocardial infarction—Sorafenib—thyroid cancer	0.00545	0.00999	CcSEcCtD
Amphetamine—Dry mouth—Vandetanib—thyroid cancer	0.00536	0.00983	CcSEcCtD
Amphetamine—SLC22A3—head—thyroid cancer	0.00534	0.021	CbGeAlD
Amphetamine—SLC18A2—lymph node—thyroid cancer	0.00525	0.0207	CbGeAlD
Amphetamine—Infection—Vandetanib—thyroid cancer	0.00522	0.00957	CcSEcCtD
Amphetamine—SLC6A4—head—thyroid cancer	0.00519	0.0205	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—PPARG—thyroid cancer	0.00496	0.0248	CbGpPWpGaD
Amphetamine—MAOB—head—thyroid cancer	0.00494	0.0195	CbGeAlD
Amphetamine—TAAR1—G alpha (s) signalling events—TSHR—thyroid cancer	0.00485	0.0242	CbGpPWpGaD
Amphetamine—Insomnia—Vandetanib—thyroid cancer	0.00476	0.00871	CcSEcCtD
Amphetamine—Erythema multiforme—Sorafenib—thyroid cancer	0.00472	0.00865	CcSEcCtD
Amphetamine—Dyspnoea—Vandetanib—thyroid cancer	0.00469	0.00859	CcSEcCtD
Amphetamine—Dyspepsia—Vandetanib—thyroid cancer	0.00463	0.00848	CcSEcCtD
Amphetamine—SLC6A2—head—thyroid cancer	0.00457	0.018	CbGeAlD
Amphetamine—Decreased appetite—Vandetanib—thyroid cancer	0.00457	0.00837	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00454	0.00832	CcSEcCtD
Amphetamine—Fatigue—Vandetanib—thyroid cancer	0.00453	0.0083	CcSEcCtD
Amphetamine—Constipation—Vandetanib—thyroid cancer	0.0045	0.00824	CcSEcCtD
Amphetamine—SLC22A5—thyroid gland—thyroid cancer	0.00437	0.0172	CbGeAlD
Amphetamine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.0043	0.00788	CcSEcCtD
Amphetamine—DRD2—head—thyroid cancer	0.00417	0.0164	CbGeAlD
Amphetamine—Body temperature increased—Vandetanib—thyroid cancer	0.00416	0.00761	CcSEcCtD
Amphetamine—Abdominal pain—Vandetanib—thyroid cancer	0.00416	0.00761	CcSEcCtD
Amphetamine—Viral infection—Epirubicin—thyroid cancer	0.00407	0.00745	CcSEcCtD
Amphetamine—Angioedema—Sorafenib—thyroid cancer	0.00397	0.00728	CcSEcCtD
Amphetamine—Dyskinesia—Epirubicin—thyroid cancer	0.00391	0.00716	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CALCB—thyroid cancer	0.0038	0.019	CbGpPWpGaD
Amphetamine—Asthenia—Vandetanib—thyroid cancer	0.00377	0.00691	CcSEcCtD
Amphetamine—Viral infection—Doxorubicin—thyroid cancer	0.00376	0.0069	CcSEcCtD
Amphetamine—Hypertension—Sorafenib—thyroid cancer	0.00375	0.00687	CcSEcCtD
Amphetamine—SLC22A3—lymph node—thyroid cancer	0.00374	0.0147	CbGeAlD
Amphetamine—TAAR1—G alpha (s) signalling events—CALCA—thyroid cancer	0.00363	0.0181	CbGpPWpGaD
Amphetamine—Dry mouth—Sorafenib—thyroid cancer	0.00362	0.00663	CcSEcCtD
Amphetamine—Dyskinesia—Doxorubicin—thyroid cancer	0.00362	0.00663	CcSEcCtD
Amphetamine—Diarrhoea—Vandetanib—thyroid cancer	0.0036	0.00659	CcSEcCtD
Amphetamine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00355	0.0065	CcSEcCtD
Amphetamine—Infection—Sorafenib—thyroid cancer	0.00352	0.00646	CcSEcCtD
Amphetamine—Dizziness—Vandetanib—thyroid cancer	0.00348	0.00637	CcSEcCtD
Amphetamine—MAOB—lymph node—thyroid cancer	0.00346	0.0136	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—PTEN—thyroid cancer	0.0034	0.017	CbGpPWpGaD
Amphetamine—Anorexia—Sorafenib—thyroid cancer	0.00338	0.00619	CcSEcCtD
Amphetamine—Vomiting—Vandetanib—thyroid cancer	0.00334	0.00612	CcSEcCtD
Amphetamine—Rash—Vandetanib—thyroid cancer	0.00332	0.00607	CcSEcCtD
Amphetamine—Dermatitis—Vandetanib—thyroid cancer	0.00331	0.00607	CcSEcCtD
Amphetamine—Headache—Vandetanib—thyroid cancer	0.00329	0.00603	CcSEcCtD
Amphetamine—SLC6A2—lymph node—thyroid cancer	0.0032	0.0126	CbGeAlD
Amphetamine—Dyspnoea—Sorafenib—thyroid cancer	0.00316	0.00579	CcSEcCtD
Amphetamine—Nausea—Vandetanib—thyroid cancer	0.00312	0.00572	CcSEcCtD
Amphetamine—Dyspepsia—Sorafenib—thyroid cancer	0.00312	0.00572	CcSEcCtD
Amphetamine—Decreased appetite—Sorafenib—thyroid cancer	0.00308	0.00565	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00306	0.00561	CcSEcCtD
Amphetamine—Fatigue—Sorafenib—thyroid cancer	0.00306	0.0056	CcSEcCtD
Amphetamine—Constipation—Sorafenib—thyroid cancer	0.00303	0.00556	CcSEcCtD
Amphetamine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.0029	0.00531	CcSEcCtD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00287	0.0143	CbGpPWpGaD
Amphetamine—Urticaria—Sorafenib—thyroid cancer	0.00282	0.00516	CcSEcCtD
Amphetamine—Body temperature increased—Sorafenib—thyroid cancer	0.0028	0.00514	CcSEcCtD
Amphetamine—Abdominal pain—Sorafenib—thyroid cancer	0.0028	0.00514	CcSEcCtD
Amphetamine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00272	0.00499	CcSEcCtD
Amphetamine—SLC22A5—lymph node—thyroid cancer	0.00272	0.0107	CbGeAlD
Amphetamine—Affect lability—Epirubicin—thyroid cancer	0.00263	0.00481	CcSEcCtD
Amphetamine—Hypersensitivity—Sorafenib—thyroid cancer	0.00261	0.00479	CcSEcCtD
Amphetamine—Asthenia—Sorafenib—thyroid cancer	0.00255	0.00466	CcSEcCtD
Amphetamine—Mood swings—Epirubicin—thyroid cancer	0.00253	0.00463	CcSEcCtD
Amphetamine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00252	0.00461	CcSEcCtD
Amphetamine—CYP2D6—head—thyroid cancer	0.0025	0.00987	CbGeAlD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00249	0.0124	CbGpPWpGaD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00248	0.0124	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00245	0.0122	CbGpPWpGaD
Amphetamine—Abdominal pain upper—Epirubicin—thyroid cancer	0.00244	0.00446	CcSEcCtD
Amphetamine—Affect lability—Doxorubicin—thyroid cancer	0.00243	0.00445	CcSEcCtD
Amphetamine—Diarrhoea—Sorafenib—thyroid cancer	0.00243	0.00445	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.0024	0.0044	CcSEcCtD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00237	0.0119	CbGpPWpGaD
Amphetamine—Dizziness—Sorafenib—thyroid cancer	0.00235	0.0043	CcSEcCtD
Amphetamine—Mood swings—Doxorubicin—thyroid cancer	0.00234	0.00428	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—TP53—thyroid cancer	0.00232	0.0116	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00231	0.0115	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00228	0.0114	CbGpPWpGaD
Amphetamine—Vomiting—Sorafenib—thyroid cancer	0.00226	0.00413	CcSEcCtD
Amphetamine—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00225	0.00413	CcSEcCtD
Amphetamine—Rash—Sorafenib—thyroid cancer	0.00224	0.0041	CcSEcCtD
Amphetamine—Dermatitis—Sorafenib—thyroid cancer	0.00223	0.00409	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00222	0.00407	CcSEcCtD
Amphetamine—Headache—Sorafenib—thyroid cancer	0.00222	0.00407	CcSEcCtD
Amphetamine—MAOB—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.0022	0.011	CbGpPWpGaD
Amphetamine—CYP2A6—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00219	0.0109	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CALCB—thyroid cancer	0.00215	0.0107	CbGpPWpGaD
Amphetamine—Nausea—Sorafenib—thyroid cancer	0.00211	0.00386	CcSEcCtD
Amphetamine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.0021	0.00385	CcSEcCtD
Amphetamine—Weight decreased—Epirubicin—thyroid cancer	0.00209	0.00382	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00204	0.00373	CcSEcCtD
Amphetamine—Urinary tract infection—Epirubicin—thyroid cancer	0.002	0.00366	CcSEcCtD
Amphetamine—Sweating—Epirubicin—thyroid cancer	0.00197	0.00361	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—CALCB—thyroid cancer	0.00195	0.00974	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00195	0.00973	CbGpPWpGaD
Amphetamine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00195	0.00357	CcSEcCtD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00193	0.00965	CbGpPWpGaD
Amphetamine—Weight decreased—Doxorubicin—thyroid cancer	0.00193	0.00354	CcSEcCtD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—thyroid cancer	0.00189	0.00943	CbGpPWpGaD
Amphetamine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00189	0.00345	CcSEcCtD
Amphetamine—Urinary tract infection—Doxorubicin—thyroid cancer	0.00185	0.00339	CcSEcCtD
Amphetamine—Sweating—Doxorubicin—thyroid cancer	0.00182	0.00334	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.0018	0.00897	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—TSHR—thyroid cancer	0.00176	0.00878	CbGpPWpGaD
Amphetamine—Erythema multiforme—Epirubicin—thyroid cancer	0.00174	0.0032	CcSEcCtD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00171	0.00855	CbGpPWpGaD
Amphetamine—Erythema multiforme—Doxorubicin—thyroid cancer	0.00161	0.00296	CcSEcCtD
Amphetamine—Tension—Epirubicin—thyroid cancer	0.00158	0.00289	CcSEcCtD
Amphetamine—Nervousness—Epirubicin—thyroid cancer	0.00156	0.00286	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.00151	0.00755	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—PTCH1—thyroid cancer	0.0015	0.00747	CbGpPWpGaD
Amphetamine—Agitation—Epirubicin—thyroid cancer	0.00148	0.0027	CcSEcCtD
Amphetamine—Tension—Doxorubicin—thyroid cancer	0.00146	0.00267	CcSEcCtD
Amphetamine—Nervousness—Doxorubicin—thyroid cancer	0.00144	0.00264	CcSEcCtD
Amphetamine—Palpitations—Epirubicin—thyroid cancer	0.00142	0.0026	CcSEcCtD
Amphetamine—Convulsion—Epirubicin—thyroid cancer	0.00139	0.00255	CcSEcCtD
Amphetamine—Hypertension—Epirubicin—thyroid cancer	0.00139	0.00254	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—SST—thyroid cancer	0.00137	0.00683	CbGpPWpGaD
Amphetamine—Chest pain—Epirubicin—thyroid cancer	0.00137	0.00251	CcSEcCtD
Amphetamine—Agitation—Doxorubicin—thyroid cancer	0.00137	0.0025	CcSEcCtD
Amphetamine—Anxiety—Epirubicin—thyroid cancer	0.00136	0.0025	CcSEcCtD
Amphetamine—Dry mouth—Epirubicin—thyroid cancer	0.00134	0.00245	CcSEcCtD
Amphetamine—CYP2A6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00132	0.0066	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CALCA—thyroid cancer	0.00132	0.00658	CbGpPWpGaD
Amphetamine—Palpitations—Doxorubicin—thyroid cancer	0.00131	0.00241	CcSEcCtD
Amphetamine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00131	0.0024	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00131	0.00652	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00131	0.00652	CbGpPWpGaD
Amphetamine—Infection—Epirubicin—thyroid cancer	0.0013	0.00239	CcSEcCtD
Amphetamine—Convulsion—Doxorubicin—thyroid cancer	0.00129	0.00236	CcSEcCtD
Amphetamine—Hypertension—Doxorubicin—thyroid cancer	0.00128	0.00235	CcSEcCtD
Amphetamine—Tachycardia—Epirubicin—thyroid cancer	0.00128	0.00234	CcSEcCtD
Amphetamine—Hyperhidrosis—Epirubicin—thyroid cancer	0.00127	0.00232	CcSEcCtD
Amphetamine—Chest pain—Doxorubicin—thyroid cancer	0.00127	0.00232	CcSEcCtD
Amphetamine—Anxiety—Doxorubicin—thyroid cancer	0.00126	0.00231	CcSEcCtD
Amphetamine—Anorexia—Epirubicin—thyroid cancer	0.00125	0.00229	CcSEcCtD
Amphetamine—Dry mouth—Doxorubicin—thyroid cancer	0.00124	0.00227	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—SLC5A5—thyroid cancer	0.00121	0.00606	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00121	0.00222	CcSEcCtD
Amphetamine—Infection—Doxorubicin—thyroid cancer	0.00121	0.00221	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—SST—thyroid cancer	0.0012	0.00597	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00119	0.00595	CbGpPWpGaD
Amphetamine—Insomnia—Epirubicin—thyroid cancer	0.00119	0.00217	CcSEcCtD
Amphetamine—Tachycardia—Doxorubicin—thyroid cancer	0.00118	0.00217	CcSEcCtD
Amphetamine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00117	0.00215	CcSEcCtD
Amphetamine—Dyspnoea—Epirubicin—thyroid cancer	0.00117	0.00214	CcSEcCtD
Amphetamine—MAOB—Biological oxidations—RXRA—thyroid cancer	0.00117	0.00583	CbGpPWpGaD
Amphetamine—Somnolence—Epirubicin—thyroid cancer	0.00117	0.00213	CcSEcCtD
Amphetamine—Anorexia—Doxorubicin—thyroid cancer	0.00116	0.00212	CcSEcCtD
Amphetamine—Dyspepsia—Epirubicin—thyroid cancer	0.00115	0.00211	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—CALCB—thyroid cancer	0.00115	0.00575	CbGpPWpGaD
Amphetamine—Decreased appetite—Epirubicin—thyroid cancer	0.00114	0.00209	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00113	0.00207	CcSEcCtD
Amphetamine—Fatigue—Epirubicin—thyroid cancer	0.00113	0.00207	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00113	0.00564	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00113	0.00564	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00113	0.00562	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00113	0.00562	CbGpPWpGaD
Amphetamine—Constipation—Epirubicin—thyroid cancer	0.00112	0.00205	CcSEcCtD
Amphetamine—Insomnia—Doxorubicin—thyroid cancer	0.0011	0.00201	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—TRIM33—thyroid cancer	0.00109	0.00545	CbGpPWpGaD
Amphetamine—Dyspnoea—Doxorubicin—thyroid cancer	0.00108	0.00198	CcSEcCtD
Amphetamine—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.00108	0.0054	CbGpPWpGaD
Amphetamine—Somnolence—Doxorubicin—thyroid cancer	0.00108	0.00198	CcSEcCtD
Amphetamine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00107	0.00196	CcSEcCtD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00107	0.00535	CbGpPWpGaD
Amphetamine—Dyspepsia—Doxorubicin—thyroid cancer	0.00107	0.00196	CcSEcCtD
Amphetamine—Decreased appetite—Doxorubicin—thyroid cancer	0.00105	0.00193	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00105	0.00192	CcSEcCtD
Amphetamine—Fatigue—Doxorubicin—thyroid cancer	0.00105	0.00192	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—SLC5A5—thyroid cancer	0.00104	0.00521	CbGpPWpGaD
Amphetamine—Urticaria—Epirubicin—thyroid cancer	0.00104	0.00191	CcSEcCtD
Amphetamine—Constipation—Doxorubicin—thyroid cancer	0.00104	0.0019	CcSEcCtD
Amphetamine—Abdominal pain—Epirubicin—thyroid cancer	0.00104	0.0019	CcSEcCtD
Amphetamine—Body temperature increased—Epirubicin—thyroid cancer	0.00104	0.0019	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—RXRA—thyroid cancer	0.00102	0.00509	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—TSHR—thyroid cancer	0.000994	0.00496	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000992	0.00182	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000978	0.00488	CbGpPWpGaD
Amphetamine—Hypersensitivity—Epirubicin—thyroid cancer	0.000966	0.00177	CcSEcCtD
Amphetamine—Urticaria—Doxorubicin—thyroid cancer	0.000964	0.00177	CcSEcCtD
Amphetamine—Abdominal pain—Doxorubicin—thyroid cancer	0.000959	0.00176	CcSEcCtD
Amphetamine—Body temperature increased—Doxorubicin—thyroid cancer	0.000959	0.00176	CcSEcCtD
Amphetamine—Asthenia—Epirubicin—thyroid cancer	0.000941	0.00172	CcSEcCtD
Amphetamine—SLC6A3—NRF2 pathway—SLC5A5—thyroid cancer	0.000925	0.00462	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—TSHR—thyroid cancer	0.000903	0.00451	CbGpPWpGaD
Amphetamine—Diarrhoea—Epirubicin—thyroid cancer	0.000897	0.00164	CcSEcCtD
Amphetamine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000894	0.00164	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000888	0.00443	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CALCB—thyroid cancer	0.000886	0.00442	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—NRG1—thyroid cancer	0.000882	0.0044	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000879	0.00439	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000879	0.00439	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—RXRA—thyroid cancer	0.000877	0.00438	CbGpPWpGaD
Amphetamine—Asthenia—Doxorubicin—thyroid cancer	0.00087	0.00159	CcSEcCtD
Amphetamine—Dizziness—Epirubicin—thyroid cancer	0.000867	0.00159	CcSEcCtD
Amphetamine—MAOB—Metabolism—MINPP1—thyroid cancer	0.000858	0.00428	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000845	0.00422	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000843	0.00421	CbGpPWpGaD
Amphetamine—Vomiting—Epirubicin—thyroid cancer	0.000834	0.00153	CcSEcCtD
Amphetamine—Diarrhoea—Doxorubicin—thyroid cancer	0.00083	0.00152	CcSEcCtD
Amphetamine—Rash—Epirubicin—thyroid cancer	0.000827	0.00151	CcSEcCtD
Amphetamine—Dermatitis—Epirubicin—thyroid cancer	0.000826	0.00151	CcSEcCtD
Amphetamine—Headache—Epirubicin—thyroid cancer	0.000821	0.0015	CcSEcCtD
Amphetamine—Dizziness—Doxorubicin—thyroid cancer	0.000802	0.00147	CcSEcCtD
Amphetamine—Nausea—Epirubicin—thyroid cancer	0.000779	0.00143	CcSEcCtD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000778	0.00389	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000778	0.00389	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—RXRA—thyroid cancer	0.000777	0.00388	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—SST—thyroid cancer	0.000773	0.00386	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SLC5A5—thyroid cancer	0.000772	0.00386	CbGpPWpGaD
Amphetamine—Vomiting—Doxorubicin—thyroid cancer	0.000771	0.00141	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—PTCH1—thyroid cancer	0.000768	0.00383	CbGpPWpGaD
Amphetamine—Rash—Doxorubicin—thyroid cancer	0.000765	0.0014	CcSEcCtD
Amphetamine—Dermatitis—Doxorubicin—thyroid cancer	0.000764	0.0014	CcSEcCtD
Amphetamine—Headache—Doxorubicin—thyroid cancer	0.00076	0.00139	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—NRG1—thyroid cancer	0.000758	0.00379	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CALCA—thyroid cancer	0.000744	0.00372	CbGpPWpGaD
Amphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000741	0.0037	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NDUFA13—thyroid cancer	0.00073	0.00364	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TCF7L1—thyroid cancer	0.000729	0.00364	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MINPP1—thyroid cancer	0.000726	0.00363	CbGpPWpGaD
Amphetamine—Nausea—Doxorubicin—thyroid cancer	0.000721	0.00132	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000718	0.00359	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—SST—thyroid cancer	0.000702	0.00351	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CHST14—thyroid cancer	0.000686	0.00343	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CALCA—thyroid cancer	0.000676	0.00337	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—NRG1—thyroid cancer	0.000672	0.00335	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000664	0.00331	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000664	0.00331	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000658	0.00328	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000653	0.00326	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—RXRA—thyroid cancer	0.000649	0.00324	CbGpPWpGaD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—TP53—thyroid cancer	0.00063	0.00315	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000623	0.00311	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NDUFA13—thyroid cancer	0.000617	0.00308	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CDK1—thyroid cancer	0.000612	0.00305	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000601	0.003	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000583	0.00291	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CHST14—thyroid cancer	0.000581	0.0029	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—CP—thyroid cancer	0.000574	0.00286	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000574	0.00286	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—CP—thyroid cancer	0.000572	0.00286	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000572	0.00286	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—RXRA—thyroid cancer	0.000569	0.00284	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000565	0.00282	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000563	0.00281	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—NRG1—thyroid cancer	0.000561	0.0028	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—HPGD—thyroid cancer	0.000553	0.00276	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000539	0.00269	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TSHR—thyroid cancer	0.000533	0.00266	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—SST—thyroid cancer	0.000527	0.00263	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000525	0.00262	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MEN1—thyroid cancer	0.000502	0.0025	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CALCB—thyroid cancer	0.000501	0.0025	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—PPARG—thyroid cancer	0.000499	0.00249	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000497	0.00248	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—BRAF—thyroid cancer	0.000477	0.00238	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—HPGD—thyroid cancer	0.000468	0.00234	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CALCB—thyroid cancer	0.000455	0.00227	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTCH1—thyroid cancer	0.000454	0.00226	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000447	0.00223	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000447	0.00223	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000439	0.00219	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00043	0.00214	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000428	0.00214	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000419	0.00209	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MINPP1—thyroid cancer	0.000418	0.00209	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000417	0.00208	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SST—thyroid cancer	0.000415	0.00207	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—TSHR—thyroid cancer	0.00041	0.00205	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CALCA—thyroid cancer	0.000399	0.00199	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000396	0.00197	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—CP—thyroid cancer	0.000396	0.00197	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000389	0.00194	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000371	0.00185	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDK1—thyroid cancer	0.000361	0.0018	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000361	0.0018	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00036	0.0018	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NDUFA13—thyroid cancer	0.000356	0.00177	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—PTCH1—thyroid cancer	0.000349	0.00174	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—PTEN—thyroid cancer	0.000342	0.00171	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CHST14—thyroid cancer	0.000334	0.00167	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000334	0.00167	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000319	0.00159	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—SST—thyroid cancer	0.000319	0.00159	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TPR—thyroid cancer	0.000318	0.00159	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PRKAR1A—thyroid cancer	0.000313	0.00156	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CALCA—thyroid cancer	0.000307	0.00153	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—PPARG—thyroid cancer	0.000305	0.00152	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000296	0.00148	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NRG1—thyroid cancer	0.00029	0.00145	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000286	0.00143	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—BRAF—thyroid cancer	0.000285	0.00142	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000281	0.0014	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HPGD—thyroid cancer	0.000269	0.00135	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TPR—thyroid cancer	0.000269	0.00134	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CALCB—thyroid cancer	0.000269	0.00134	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PRKAR1A—thyroid cancer	0.000264	0.00132	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TERT—thyroid cancer	0.00026	0.0013	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TRIM33—thyroid cancer	0.000255	0.00127	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HIF1A—thyroid cancer	0.000249	0.00124	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000249	0.00124	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SLC5A5—thyroid cancer	0.000238	0.00119	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MINPP1—thyroid cancer	0.000234	0.00117	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—thyroid cancer	0.000233	0.00117	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—TSHR—thyroid cancer	0.000232	0.00116	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—NRAS—thyroid cancer	0.000219	0.0011	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—HRAS—thyroid cancer	0.000219	0.0011	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—TSHR—thyroid cancer	0.000211	0.00105	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—PTEN—thyroid cancer	0.000209	0.00104	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000207	0.00103	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—BRAF—thyroid cancer	0.000206	0.00103	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SLC5A5—thyroid cancer	0.000201	0.001	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—RXRA—thyroid cancer	0.0002	0.000997	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	0.000199	0.000995	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—KRAS—thyroid cancer	0.000189	0.000943	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CHST14—thyroid cancer	0.000187	0.000936	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—SST—thyroid cancer	0.00018	0.0009	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTCH1—thyroid cancer	0.000179	0.000894	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CALCA—thyroid cancer	0.000174	0.000867	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000171	0.000852	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TCF7L1—thyroid cancer	0.00017	0.000848	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—RXRA—thyroid cancer	0.000169	0.000844	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—SST—thyroid cancer	0.000164	0.000818	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HRAS—thyroid cancer	0.000161	0.000802	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CALCA—thyroid cancer	0.000158	0.000787	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AKT1—thyroid cancer	0.000156	0.000779	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TPR—thyroid cancer	0.000155	0.000773	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PRKAR1A—thyroid cancer	0.000152	0.00076	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HPGD—thyroid cancer	0.000151	0.000754	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCND1—thyroid cancer	0.000151	0.000752	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTEN—thyroid cancer	0.000145	0.000725	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—thyroid cancer	0.000143	0.000713	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CDK1—thyroid cancer	0.000143	0.000712	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AKT1—thyroid cancer	0.000142	0.000708	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—HRAS—thyroid cancer	0.000131	0.000653	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NRAS—thyroid cancer	0.00013	0.000647	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPARG—thyroid cancer	0.000126	0.00063	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TSHR—thyroid cancer	0.000124	0.000621	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PRKAR1A—thyroid cancer	0.000122	0.000611	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MEN1—thyroid cancer	0.000117	0.000584	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC5A5—thyroid cancer	0.000116	0.000578	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KRAS—thyroid cancer	0.000112	0.000557	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARG—thyroid cancer	0.000107	0.000533	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTCH1—thyroid cancer	0.000106	0.000528	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—thyroid cancer	9.92e-05	0.000495	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—thyroid cancer	9.92e-05	0.000495	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—RXRA—thyroid cancer	9.73e-05	0.000486	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SST—thyroid cancer	9.67e-05	0.000483	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HRAS—thyroid cancer	9.48e-05	0.000474	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CALCA—thyroid cancer	9.31e-05	0.000465	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TPR—thyroid cancer	8.68e-05	0.000433	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTEN—thyroid cancer	8.65e-05	0.000432	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	8.54e-05	0.000426	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDK1—thyroid cancer	8.43e-05	0.000421	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—thyroid cancer	8.4e-05	0.000419	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKT1—thyroid cancer	8.37e-05	0.000418	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTEN—thyroid cancer	7.32e-05	0.000366	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NRG1—thyroid cancer	6.77e-05	0.000338	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	6.5e-05	0.000324	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARG—thyroid cancer	6.15e-05	0.000307	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TERT—thyroid cancer	6.08e-05	0.000303	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HIF1A—thyroid cancer	5.81e-05	0.00029	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—RXRA—thyroid cancer	5.46e-05	0.000272	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NRAS—thyroid cancer	5.12e-05	0.000256	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKT1—thyroid cancer	4.99e-05	0.000249	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—thyroid cancer	4.83e-05	0.000241	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—BRAF—thyroid cancer	4.81e-05	0.00024	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KRAS—thyroid cancer	4.41e-05	0.00022	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKT1—thyroid cancer	4.22e-05	0.000211	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTEN—thyroid cancer	4.22e-05	0.00021	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HRAS—thyroid cancer	3.74e-05	0.000187	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	3.64e-05	0.000182	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCND1—thyroid cancer	3.51e-05	0.000175	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARG—thyroid cancer	3.45e-05	0.000172	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTEN—thyroid cancer	3.39e-05	0.000169	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT1—thyroid cancer	3.31e-05	0.000165	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NRAS—thyroid cancer	3.02e-05	0.000151	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—thyroid cancer	2.71e-05	0.000135	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KRAS—thyroid cancer	2.6e-05	0.00013	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKT1—thyroid cancer	2.43e-05	0.000121	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTEN—thyroid cancer	2.36e-05	0.000118	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—thyroid cancer	2.31e-05	0.000115	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HRAS—thyroid cancer	2.21e-05	0.00011	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT1—thyroid cancer	1.95e-05	9.75e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKT1—thyroid cancer	1.36e-05	6.8e-05	CbGpPWpGaD
